Merck & Co Newsroom

Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock

Kevin Travers11:24 ET

Merck Ends Development of Two Experimental Cancer Drugs

Zacks Dec 17 08:30 ET

Merck's Respiratory Syncytial Virus Drug's Biologics License Application Accepted by FDA

MT NewswiresDec 17 07:36 ET

Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Yahoo FinanceDec 17 07:18 ET

Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate

WSJDec 17 07:11 ET

Express News | Merck & Co Inc - if Approved, Anticipates Clesrovimab Available for Ordering by July 2025

ReutersDec 17 06:45 ET

Express News | Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants From Rsv Disease During Their First Rsv Season

ReutersDec 17 06:45 ET

Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110

Moomoo NewsDec 16 20:32 ET · Ratings

Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123

Moomoo NewsDec 16 20:32 ET · Ratings

Bernstein Keeps Their Hold Rating on Merck & Company (MRK)

TipRanksDec 16 19:59 ET · Ratings

Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

BenzingaDec 16 16:33 ET

Express News | Merck & Co Inc - Patients in Keyform-008 Trial May Continue Therapy Until Study Completion

ReutersDec 16 16:30 ET

Express News | Merck & Co Inc - Discontinues Clinical Development Programs for Vibostolimab and Favezelimab

ReutersDec 16 16:30 ET

Express News | Merck Provides Update on Keyvibe and Keyform Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab

ReutersDec 16 16:30 ET

Another Week, Another Index Record | Lkive Stock

Kevin TraversDec 16 10:42 ET

Dow's 115-Point Rally Highlighted By Gains In Honeywell, Nike Shares

MarketWatchDec 16 10:08 ET

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

Zacks Dec 16 10:05 ET

Merck's KEYTRUDA Approved in Combination With Chemotherapy in China to Treat Lung Cancer

MT NewswiresDec 16 07:14 ET

Express News | Merck’s Keytruda® (Pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, Iiia or Iiib Nsclc

ReutersDec 16 06:45 ET

Weekly Buzz: Tech stocks hit high scores on ominous day

Kevin TraversDec 13 16:29 ET